Women’s Health Went Home. Nanopath Bet $25 Million On The Exam Room

vaginitis test, Nanopath; women's health diagnostics; point-of-care testing; Series B funding; Labcorp Ventures; Norwest; Alison Burklund; Amogha Tadimety; urinary tract infection; FDA Breakthrough Device designation
Nanopath’s BSL-2 laboratory at The Engine in Cambridge, Mass., where the company is developing a 15-minute vaginitis test for use in doctors’ offices.

Half of women who came to a clinic with vaginal symptoms but had no infection still got antimicrobial treatment under usual care, according to a randomized study published in May. Nanopath, a Cambridge, Massachusetts,women’s health diagnostics startup, just raised a$25 million Series B to end guesswork with a 15-minute vaginitis test built for the doctor’s office.

Norwest and the Medtech Convergence Fund, an SV Health Investors venture fund, co-led the round, with strategic participation from Labcorp Ventures. The company has now raised more than $46 million. Its co-CEOs, Alison Burklund and Amogha Tadimety, are making a contrarian bet: While many women’s health startups sell at-home tests that women pay for themselves, Nanopath built one that lives in the exam room and gets billed to insurance.

Nanopath Bets On The Exam Room, Not At-Home Testing

vaginitis test, Nanopath; women's health diagnostics; point-of-care testing; Series B funding; Labcorp Ventures; Norwest; Alison Burklund; Amogha Tadimety; urinary tract infection; FDA Breakthrough Device designation
Nanopath co-founders and co-CEOs Dr. Amogha Tadimety (left) and Dr. Alison Burklund (right), whose company raised a $25 million Series B for its 15-minute vaginitis test.

The tools clinicians use to diagnose infections in women during a visit “really haven’t been innovated on in over 50 years, limited to microscopy, urine dips, pregnancy tests,” says Burklund. For vaginitis, that often means a clinician looking at a swab under a microscope, which she calls “incredibly inaccurate.”

Much of the market has answered by moving testing home. In March 2025, the Food and Drug Administration authorized Visby Medical’s chlamydia, gonorrhea, and trichomoniasis test as the first of its kind that women can buy over the counter. Evvy sells vaginal microbiome tests directly to consumers.

Nanopath went the other way. “This will be reimbursed,” Burklund states. The goal is “a drop-in test for what now exists in the centralized laboratory,” billed under an existing code she says has “over 90% coverage on both public and private payers.” Insurance billing is also how the founders plan to reach women who “can’t necessarily afford to pay X number of dollars out of pocket.”

Patient preference backs the choice, Tadimety argues. Women “really do want to see their provider” for counseling and a treatment plan. For cervical cancer screening, 60.8% of 2,300 women in a national surveypreferred a clinic, compared with 20.4% who preferred testing at home.

Vaginitis Comes First, Urinary Tract Infections Second

Burklund and Tadimety spun Nanopath out of their PhD work at Dartmouth’s engineering school. Their optical biosensing technology detects DNA and RNA without the amplification step that standard PCR tests need. More than 100 conversations with clinicians steered them away from hospitals. Burklund recalls learning that “hospital sales cycles take years. As a small company, we could not fight that.”

The founders then ran what Tadimety calls a “secondary indication prioritization effort,” scoring vaginitis, sexually transmitted infections, urinary tract infections, HPV, and Group B strep on competition, market size, clinical need, reimbursement, and regulation. Vaginitis came out on top because of “a tremendous need” and “a relatively low-risk regulatory and reimbursement path,” she explains, with existing lab tests to compare against. The test checks for bacterial vaginosis, yeast, and trichomoniasis. Vaginitis alone accounts formore than 10 million office visits a year.

That choice stands out because Nanopath’s most prestigious credential belongs to another test. In November 2025, the FDA granted Breakthrough Device designation to its test for complicated urinary tract infections, which identifies the bacteria and antibiotic-resistance markers. That test now sits “a half step behind,” Tadimety says, with the designation buying closer FDA input on a harder study design.

In her view, the neglect of these infections is no accident. As the founders often say to each other, “If men had UTIs at the same rate as women, there would be a better solution.”

A 15-Minute Test Built For A 20-Minute Appointment

Speed is the business case. A clinician might see 30 patients a day on a 20-minute schedule, Tadimety notes, so “15 minutes versus 20 minutes versus 25 minutes is materially impactful.” When she and Burklund interviewed clinicians, “the OB/GYNs were screaming for help,” she adds, because they had to wait for lab results and then chase patients by phone to change treatment. In a blinded survey of more than 130 physicians that Nanopath conducted, clinicians reported spending 8 to 10 hours a week calling patients back with results.

Guessing carries a cost. Ina study of women with vaginal discharge in community practices, 42% did not get the appropriate prescription. Women without an infection who were treated anyway were more likely to come back within 90 days. Aclaims analysis funded by HealthTrackRx, a lab that sells molecular vaginitis testing, found six-month healthcare costs about $1,000 lower for women who got a lab-based molecular test than for women who got no test.

In-office molecular testing already exists. Cepheid’s Xpert Xpress MVP vaginitis panel won FDA clearance and a waiver to run in outpatient offices in January 2024, with results in about an hour. It is also the test behind the study above, which found that 89.6% of women with infections got appropriate treatment within 24 hours when tested in the office, compared with 51.9% under usual care. Burklund asks, “Will the patient wait for an hour?”

Clinicians see the value of a faster answer. “Having accurate molecular results in under 15 minutes could be transformative, allowing providers to provide targeted treatment while the patient is still in the room,” says Paul Nyirjesy, MD, professor of obstetrics and gynecology, and cofounder of the Jefferson Vulvovaginal Health Center at Sidney Kimmel Medical College at Thomas Jefferson University.

Grants And A $25 Million Series B Funded The Path To FDA

Many founders brag about how much they raise. Burklund would rather “brag about how little money we’ve raised and how much progress we’ve made on those dollars.”

Nanopath has brought in about $4.5 million in non-dilutive grants, including Small Business Innovation Research grants from the National Institutes of Health and the National Science Foundation, according to the company. NIH funding produced the urinary tract infection data behind the Breakthrough designation, while venture capital pays for the vaginitis product. The founders also avoided building an “all-powerful C-suite when we’re only 15 people,” Burklund says. The company now has 24 full-time employees.

Equity came in stages: a $1 million seed round in 2020 and a $6 million Series A extension in 2025, according to the company. The Series B brought back the same two investors that co-led Nanopath’s $10 million Series A in 2022.

“Nanopath is developing truly transformative technology with the potential to reshape the molecular diagnostics industry and dramatically improve patient outcomes,” says Jeff Crowe, senior managing partner at Norwest.

Aaron Sandoski, managing director at Norwich Ventures and founding partner at Medtech Convergence Fund, points to the technology itself. The founders have pushed forward “a very ambitious product platform that has now been technologically de-risked.”

Labcorp’s participation adds a different signal. A company built on centralized lab testing is now backing a test designed to work outside the lab. Mindy Nye, PhD, vice president, Office of the CSO at Labcorp, joined Nanopath’s board as an observer, as did Catherine Kiani, JD, managing partner at Elderberry Ventures.

The money funds manufacturing scale-up, an FDA 510(k) clinical study across “10 or 15 sites,” and testing to win a waiver for use in outpatient offices. Nanopath expects to start the pivotal study supporting its FDA submission within the next 12 to 18 months, the company says.

What Founders Can Learn From Nanopath’s Co-CEOs

The founders’ first lesson is for scientists like them. Inventors tend to believe the platform will sell itself, and “we tend to underweight the business model piece of this,” Burklund admits.

Their second lesson is about evidence. Tadimety reflects that “we’re very lucky that the data points to something that we are passionate about.”

Their third lesson is about shared leadership. The two have run Nanopath together since its founding and formalized their co-CEO titles after the Series A. They split work by interest and make core decisions together, a structure that proved its worth when Tadimety took maternity leave. “I had a baby nine months ago, and I was able to step away. And the secret weapon was having Alison here,” she recalls. Nanopath is majority women, and its board “has officially tipped the scales to be more women than men,” Burklund says.

Many of Nanopath’s academic collaborators work in the South, where these infections are most common. That is where the founders measure success. “We will feel like we have failed if the technology just sits in Cambridge,” Burklund says.

This article was originally published on Forbes.com

Author: Health Watch Minute

Health Watch Minute Provides the latest health information, from around the globe.

Leave a Reply

Your email address will not be published. Required fields are marked *